GO:0003823 antigen binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003823 antigen binding is a molecular function describing the selective binding of an antigen by an antibody, B cell receptor, or MHC protein complex.
• Antigen binding underlies adaptive immunity, enabling antibodies and T cell receptors to recognize pathogens, tumors, and allergens.
• MHC proteins use antigen binding to display peptide or lipid antigens to T cells and NK cells, a process modulated by post-translational modifications.
• Antigen binding affinity and valency influence therapeutic antibody pharmacokinetics and antigen mass effects in humans.
• Calcium-dependent antigen binding provides a mechanism for antibody recycling via endosomal antigen dissociation.
• CRISPR-based knockout, knock-in, and point-mutation models are essential to dissect the causal roles of genes encoding antigen-binding proteins.
Description
Antigen binding (GO:0003823) is a molecular function defined as the binding to an antigen, any substance capable of inducing a specific immune response and of reacting with the products of that response, the specific antibody or specifically sensitized T-lymphocytes, or both. This function is central to adaptive immunity and is mediated by immunoglobulins, T cell receptors, and major histocompatibility complex (MHC) proteins. The QuickGO definition emphasizes that binding may counteract the biological activity of the antigen and that antigen binding by an MHC protein complex allows the antigen to be displayed to a T cell or NK cell. Researchers study antigen binding to understand host-pathogen interactions, vaccine design, autoimmunity, and cancer immunotherapy. The specificity and affinity of antigen binding are governed by the structural complementarity between the binding site and the antigenic determinant, as illustrated by the molecular mapping of the senescent cell antigen on band 3 membrane transport protein. Moreover, antigen binding is not static; post-translational modifications can reshape the antigenic landscape of the MHC I immunopeptidome in tumors, thereby altering immune recognition. In therapeutic settings, antigen mass significantly influences the pharmacokinetics of therapeutic antibodies in humans, underscoring the clinical relevance of this function. Advanced omics techniques have further shed light on CD1d-mediated lipid antigen presentation to iNKT cells, expanding the scope of antigen binding beyond peptides. Thus, GO:0003823 encompasses a diverse set of molecular interactions that are fundamental to immune surveillance and immunotherapy.
antigen binding At A Glance
| GO ID | GO:0003823 |
|---|---|
| GO term | antigen binding |
| Ontology | molecular_function |
| Synonym | antibody activity, B cell receptor activity, major histocompatibility complex activity, major histocompatibility complex antigen display activity, MHC activity, opsonin activity |
| Major function | Binding to an antigen, any substance capable of inducing a specific immune response and of reacting with the products of that response, the specific antibody or specifically sensitized T-lymphocytes, or both. |
| Definition source | QuickGO |
| Related cellular component | MHC protein complex, B cell receptor complex, T cell receptor complex |
| Related biological process | Immune response, antigen presentation, humoral immunity |
What Is GO:0003823?
In our own words, antigen binding (GO:0003823) is the molecular function by which a protein selectively recognizes and physically interacts with an antigen. This antigen can be any foreign or self substance that elicits an immune response, and the binding protein may be an antibody, a B cell receptor, a T cell receptor, or an MHC molecule. The binding event can neutralize the antigen's biological activity or, in the case of MHC proteins, present the antigen to T cells or NK cells for immune surveillance. The function is characterized by specificity, affinity, and in some cases, dependence on cofactors such as calcium ions.
Why Is antigen binding Important in Cell Biology?
Antigen binding is a cornerstone of adaptive immunity and is essential for defending the host against pathogens, eliminating transformed cells, and mediating allergic and autoimmune reactions. The specificity of antigen binding determines the efficacy of vaccines and therapeutic antibodies, and its dysregulation can lead to immunodeficiency or autoimmunity. Understanding the molecular details of antigen binding, including the role of post-translational modifications and antigen mass, is critical for designing next-generation immunotherapies and diagnostics.
• Enables antibodies and B cell receptors to neutralize pathogens and toxins.
• Allows MHC proteins to display antigens to T cells and NK cells, initiating adaptive immune responses.
• Underlies the mechanism of action of therapeutic antibodies used in cancer and autoimmune diseases.
• Influences vaccine design by defining which antigenic epitopes are recognized.
• Modulates antibody pharmacokinetics through antigen mass and affinity.
• Provides a target for engineering calcium-dependent antigen binding to enhance antibody recycling.
• Is implicated in aging through the senescent cell antigen on band 3.
• Can be exploited for antigen-adjuvant conjugation to improve immunogenicity.
• Plays a role in lipid antigen presentation by CD1d to iNKT cells.
• Is a key parameter in the structural and functional characterization of influenza hemagglutinin antigenicity.
What Happens During antigen binding?
Antigen Recognition and Initial Contact
In simple terms: The binding protein first encounters and recognizes a specific antigen.
Antigen binding begins with the recognition of an antigenic determinant by the variable regions of an antibody or T cell receptor, or by the peptide-binding groove of an MHC molecule. This recognition is highly specific and depends on non-covalent interactions such as hydrogen bonds, electrostatic forces, and hydrophobic effects. For MHC class I, the antigenic landscape can be reshaped by post-translational modifications, which alter the repertoire of peptides presented to T cells. In the case of the senescent cell antigen, lysine residues on an anion-binding segment of band 3 are required for antigenicity, highlighting the chemical basis of recognition.
Conformational Changes and Binding Affinity
In simple terms: Binding often induces shape changes that strengthen the interaction.
Upon initial contact, conformational changes in the binding protein and/or the antigen can occur, leading to a tighter fit and higher affinity. For example, calcium-dependent antigen binding in antibodies allows for a reversible interaction that is sensitive to endosomal calcium concentrations, facilitating antigen dissociation and antibody recycling. The affinity of antigen binding is a critical determinant of the biological outcome, as seen in the pharmacokinetics of therapeutic antibodies where antigen mass influences clearance.
Antigen Display and Immune Cell Activation
In simple terms: MHC proteins present the antigen to immune cells, triggering a response.
When MHC proteins bind antigen, they display it on the cell surface to T cells or NK cells. This antigen display is a prerequisite for T cell activation and the initiation of adaptive immune responses. The QuickGO definition explicitly states that antigen binding by an MHC protein complex allows the antigen to be displayed to a T cell or NK cell. CD1d molecules similarly present lipid antigens to iNKT cells, a process that has been illuminated by advanced omics techniques.
Neutralization and Effector Functions
In simple terms: Antibodies can block the antigen's activity or mark it for destruction.
Antigen binding by antibodies can neutralize the biological activity of the antigen, such as preventing a virus from entering a host cell. Additionally, binding can opsonize the antigen, promoting its uptake and destruction by phagocytes. The QuickGO definition notes that binding may counteract the biological activity of the antigen. In influenza, antigenic drift expands viral escape pathways from recalled humoral immunity, demonstrating the dynamic interplay between antigen binding and viral evolution.
Regulation by Post-Translational Modifications
In simple terms: Chemical modifications on antigens or binding proteins can alter binding outcomes.
Post-translational modifications such as phosphorylation, glycosylation, and ubiquitination can reshape the antigenic landscape of the MHC I immunopeptidome in tumors, thereby affecting antigen binding and immune recognition. These modifications can create neoepitopes or mask existing epitopes, influencing the efficacy of immunotherapies. Understanding these regulatory layers is essential for predicting antigen binding in disease contexts.
Key Genes Involved in GO:0003823 antigen binding
The following genes encode proteins that directly mediate or regulate antigen binding, including immunoglobulins, T cell receptors, MHC molecules, and antigen processing components.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGHG1 | Immunoglobulin heavy constant gamma 1; forms antibody heavy chain | Therapeutic antibody engineering; antigen binding affinity studies |
| IGKC | Immunoglobulin kappa constant; forms antibody light chain | Antibody structure-function; knockout models for B cell development |
| HLA-A | MHC class I heavy chain; presents peptide antigens to CD8+ T cells | Tumor immunopeptidome; post-translational modification effects |
| HLA-B | MHC class I heavy chain; presents peptide antigens | Infectious disease susceptibility; antigen presentation studies |
| HLA-DRA | MHC class II alpha chain; presents peptide antigens to CD4+ T cells | Autoimmunity; antigen binding and presentation |
| B2M | Beta-2-microglobulin; light chain of MHC class I | MHC class I assembly and antigen display; knockout models |
| CD1D | Presents lipid antigens to iNKT cells | Lipid antigen presentation; iNKT cell activation |
| TRAC | T cell receptor alpha constant; forms TCR alpha chain | T cell receptor antigen binding; CRISPR knockout for TCR function |
| TRBC1 | T cell receptor beta constant 1; forms TCR beta chain | TCR specificity; antigen binding studies |
| SLC4A1 | Band 3 anion transport protein; carries senescent cell antigen | Aging antigen; lysine-dependent antigenicity |
| CALR | Calreticulin; chaperone for MHC class I assembly | Antigen processing and loading; knockout affects antigen presentation |
| TAP1 | Transporter associated with antigen processing 1 | Peptide transport for MHC class I; antigen binding indirectly |
| TAP2 | Transporter associated with antigen processing 2 | Peptide transport for MHC class I |
| PSMB8 | Immunoproteasome subunit beta 8; generates peptides for MHC I | Antigen processing; knockout alters immunopeptidome |
| PSMB9 | Immunoproteasome subunit beta 9; generates peptides for MHC I | Antigen processing; immunopeptidome modulation |
| CANX | Calnexin; chaperone for MHC class I heavy chain | MHC class I folding and antigen binding |
| PDIA3 | Protein disulfide isomerase A3; part of peptide-loading complex | MHC class I peptide loading; antigen binding |
| LGMN | Legumain; lysosomal protease for antigen processing | MHC class II antigen processing; knockout models |
How Is antigen binding Regulated?
Antigen binding is regulated at multiple levels, including the availability of antigen, the expression of binding proteins, and post-translational modifications. For MHC class I, the immunopeptidome is dynamically regulated by the immunoproteasome and post-translational modifications that reshape the antigenic landscape in tumors. Calcium-dependent antigen binding in antibodies is regulated by endosomal calcium concentrations, enabling pH- and ion-dependent recycling. Antigen mass also regulates the pharmacokinetics of therapeutic antibodies, as high antigen loads can accelerate antibody clearance. Additionally, antigenic drift in influenza virus alters the antigenic sites of hemagglutinin, allowing escape from pre-existing antibodies. These regulatory mechanisms ensure that antigen binding is context-dependent and finely tuned.
antigen binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-A | Cancer immunopeptidome; immune evasion | Knockout in tumor cell lines followed by immunopeptidomics |
| SLC4A1 | Aging; senescent cell antigen clearance | Point mutation of lysine residues in band 3; binding assays |
| CD1D | Autoimmunity; lipid antigen presentation | Knockout mice or cell lines; iNKT cell activation assays |
| IGHG1 | Therapeutic antibody pharmacokinetics | Knock-in of variant Fc regions; antigen mass studies |
| B2M | MHC class I deficiency; cancer immune escape | CRISPR knockout in cancer cell lines; antigen presentation assays |
Cancer and the MHC I Immunopeptidome
In cancer, post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome, leading to altered antigen binding and immune evasion. Tumor-specific neoepitopes can be generated or masked, affecting the efficacy of immunotherapies such as checkpoint inhibitors. Understanding these modifications is crucial for developing personalized cancer vaccines and T cell therapies.
Infectious Diseases and Antigenic Drift
Antigenic drift in influenza virus expands viral escape pathways from recalled humoral immunity, as mutations in hemagglutinin reduce antibody binding. Structural and functional characterization of influenza A virus hemagglutinin subtype H15 has provided insights into antigenicity and receptor binding. These studies inform vaccine strain selection and antiviral strategies.
Autoimmunity and Aging
The senescent cell antigen on band 3 membrane transport protein requires lysine residues for antigenicity, and its binding by autoantibodies contributes to the clearance of aged red blood cells. This exemplifies how antigen binding can target self-antigens in aging and autoimmune contexts. Dysregulated antigen binding to self-molecules underlies autoimmune diseases such as systemic lupus erythematosus.
Lipid Antigen Presentation and iNKT Cells
CD1d-mediated lipid antigen presentation to iNKT cells is a specialized form of antigen binding that bridges innate and adaptive immunity. Advanced omics techniques have shed light on the lipid antigens and the molecular interactions involved. Defects in this pathway are associated with autoimmune and inflammatory disorders.
From antigen binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HLA-A alter antigen binding and presentation? | HLA-A knockout cell line (CRISPR-Cas9) |
| How do post-translational modifications affect MHC I immunopeptidome? | Point mutations at modification sites in HLA-A; immunopeptidomics |
| Can calcium-dependent antigen binding enhance antibody recycling? | Knock-in of calcium-binding motif into antibody gene; endosomal dissociation assays |
| What is the role of CD1d in lipid antigen presentation? | CD1d overexpression or knockout in antigen-presenting cells; iNKT cell co-culture |
| How does antigen mass influence antibody pharmacokinetics? | Knock-in of target antigen at varying expression levels; PK studies |
| Does antigenic drift in hemagglutinin affect antibody binding? | Point mutations in influenza HA; binding assays with monoclonal antibodies |
How to Study the antigen binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunopeptidomics | Peptides bound to MHC molecules | Tumor antigen discovery; post-translational modification effects |
| Surface Plasmon Resonance | Binding affinity and kinetics | Antibody engineering; antigen binding characterization |
| Biolayer Interferometry | Binding affinity and kinetics | Therapeutic antibody screening |
| CRISPR knockout screens | Genes regulating antigen binding | Identification of novel immune modulators |
| Flow cytometry | Cell surface antigen binding | MHC tetramer staining; T cell receptor binding |
| ELISPOT | Cytokine secretion upon antigen binding | T cell activation assays |
| Lipidomics | Lipid antigen profiles | CD1d-mediated antigen presentation |
| Structural biology (cryo-EM, X-ray) | 3D structure of antigen-binding complexes | Influenza hemagglutinin antigenicity |
Immunopeptidomics and Mass Spectrometry
Immunopeptidomics uses mass spectrometry to identify peptides bound to MHC molecules, providing a snapshot of the antigenic landscape. This method has been instrumental in revealing how post-translational modifications reshape the MHC I immunopeptidome in tumors. It allows researchers to quantify antigen binding specificity and identify neoepitopes for immunotherapy.
Surface Plasmon Resonance (SPR) and Biolayer Interferometry (BLI)
SPR and BLI measure real-time binding kinetics between antigens and antibodies or MHC proteins. These label-free techniques provide affinity constants (KD) and kinetic rates (kon, koff), which are critical for understanding antigen binding strength. They are widely used to characterize therapeutic antibodies and engineered binding proteins.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that regulate antigen binding and presentation. For example, screens targeting MHC class I pathway components have uncovered modifiers of antigen display. These screens are powerful for discovering novel regulators of antigen binding in cancer and infectious disease.
Advanced Omics for Lipid Antigen Presentation
Advanced omics techniques, including lipidomics and transcriptomics, have shed light on CD1d-mediated lipid antigen presentation to iNKT cells. These approaches enable the comprehensive analysis of lipid antigens and the genes involved in their presentation, offering insights into immune regulation.
How CRISPR Can Be Used to Study GO:0003823 antigen binding
Knockout
CRISPR knockout of genes encoding antigen-binding proteins, such as HLA-A or B2M, abolishes antigen presentation and allows researchers to study the consequences of loss of antigen binding on immune recognition. Knockout models are essential for validating the role of specific genes in antigen binding and for identifying compensatory pathways.
Point Mutation
Point mutations can be introduced into genes encoding antigen-binding proteins to dissect the contribution of specific residues to binding affinity and specificity. For example, mutating lysine residues in band 3 (SLC4A1) can abolish senescent cell antigenicity, providing insights into the molecular basis of antigen binding. Similarly, point mutations in influenza hemagglutinin can mimic antigenic drift and alter antibody binding.
Knock-in
Knock-in of variant antigen-binding domains or reporter tags allows for precise tracking and functional analysis. For instance, knocking in a calcium-binding motif into an antibody gene can confer calcium-dependent antigen binding, enabling endosomal recycling. Knock-in models are also used to study the effect of antigen mass on antibody pharmacokinetics by expressing target antigens at defined levels.
Overexpression
Overexpression of antigen-binding proteins, such as MHC class I or CD1d, can enhance antigen presentation and immune activation. Overexpression models are useful for studying the downstream effects of increased antigen binding, including T cell activation and cytokine production. They also facilitate structural and biochemical studies by providing ample protein for purification.
How EDITGENE Supports antigen binding Research
Researchers studying antigen binding-related genes often need to determine whether a candidate gene is causally involved in antigen recognition, presentation, or immune evasion. CRISPR-based models provide a robust way to manipulate these genes in relevant cell types and to interrogate their functions in disease contexts.
Contact EDITGENE today to design your custom CRISPR model for antigen binding research.
Frequently Asked Questions About antigen binding
What is antigen binding (GO:0003823)?
Antigen binding is a molecular function defined as the binding to an antigen, any substance capable of inducing a specific immune response and of reacting with the products of that response, the specific antibody or specifically sensitized T-lymphocytes, or both.
What genes are involved in antigen binding?
Key genes include IGHG1, IGKC, HLA-A, HLA-B, HLA-DRA, B2M, CD1D, TRAC, TRBC1, SLC4A1, and antigen processing genes such as TAP1, PSMB8, and PSMB9.
How does MHC antigen binding work?
MHC proteins bind peptide or lipid antigens in a groove and display them on the cell surface to T cells or NK cells, as stated in the QuickGO definition.
What is the role of post-translational modifications in antigen binding?
Post-translational modifications can reshape the antigenic landscape of the MHC I immunopeptidome in tumors, altering which antigens are bound and presented.
How does antigen mass affect antibody pharmacokinetics?
Antigen mass influences the clearance of therapeutic antibodies in humans, with higher antigen loads often leading to faster antibody elimination.
What is calcium-dependent antigen binding?
Calcium-dependent antigen binding is a modality where antibody binding to antigen is regulated by calcium ions, enabling endosomal antigen dissociation and antibody recycling.
Which diseases are associated with defective antigen binding?
Defective antigen binding is associated with cancer immune evasion, infectious diseases such as influenza, autoimmune disorders, and aging-related clearance of senescent cells.
How can CRISPR be used to study antigen binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to manipulate genes encoding antigen-binding proteins and assess the effects on immune recognition.
What methods are used to measure antigen binding?
Common methods include immunopeptidomics, surface plasmon resonance, biolayer interferometry, flow cytometry, and ELISPOT.
What is the clinical relevance of antigen binding?
Antigen binding is central to vaccine design, therapeutic antibody development, cancer immunotherapy, and understanding infectious disease escape mechanisms.
Conclusion
Antigen binding (GO:0003823) is a fundamental molecular function that governs adaptive immunity, from antibody neutralization to MHC-mediated antigen display. Its specificity and regulation are critical for health and disease, influencing cancer, infections, autoimmunity, and aging. Continued research using CRISPR models and advanced omics will unravel the complexities of antigen binding and translate these insights into novel therapies.
References
- 1. Kacen A et al.. 2023. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.. Nat Biotechnol 41(2):239-251 PMID: 36203013
- 2. Maurer DP et al.. 2025. Antigenic drift expands influenza viral escape pathways from recalled humoral immunity.. Immunity 58(3):716-727.e6 PMID: 40023162
- 3. Hironiwa N et al.. 2016. Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation.. MAbs 8(1):65-73 PMID: 26496237
- 4. Kay MM et al.. 1990. Molecular mapping of the active site of an aging antigen: senescent cell antigen requires lysine(s) for antigenicity and is located on an anion-binding segment of band 3 membrane transport protein.. Gerontology 36(5-6):293-305 PMID: 1706294
- 5. Ternant D et al.. 2019. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.. Clin Pharmacokinet 58(2):169-187 PMID: 29802542
- 6. Sun Y et al.. 2025. A Click-Type Enzymatic Method for Antigen-Adjuvant Conjugation.. Small Methods 9(3):e2401116 PMID: 39177201
- 7. Bhavsar D et al.. 2026. Structural and functional characterization of the antigenicity of influenza A virus hemagglutinin subtype H15.. Cell Rep 45(1):116773 PMID: 41485218
- 8. Morris I et al.. 2023. Advanced omics techniques shed light on CD1d-mediated lipid antigen presentation to iNKT cells.. Biochim Biophys Acta Mol Cell Biol Lipids 1868(5):159292 PMID: 36773690
